GlassScriptPhysician profile
Pooja Lahoti
NPI 1750657524
$2,789.12
in general payments reported to CMS, 2019-2025
34 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $880 · 2024: $762 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,769.50 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $417.40 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $392.30 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $344.66 | 2023-2025 | |
| Lilly USA, LLC | $227.18 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $180.30 | 2023-2025 | |
| Novo Nordisk INC | $158.21 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $128.38 | 2023-2025 | Auvelity, Sunosi |
| Glaxosmithkline, LLC. | $118.64 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $109.15 | 2025 | Otezla, Repatha, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.25 | 2025 | Caplyta |
| Exact Sciences Corporation | $69.98 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.98 | 2023-2025 | Trulance, Xifaxan, Relistor |
| Otsuka America Pharmaceutical, INC. | $51.65 | 2023-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $34.46 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $33.76 | 2025 | Trintellix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $29.79 | 2023 | Sucraid |
| Merck Sharp & Dohme LLC | $29.00 | 2023-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Janssen Pharmaceuticals, INC | $28.74 | 2023 | Xarelto |
| Medtronic, INC. | $26.05 | 2025 | Inceptiv |
| Dexcom, INC. | $21.26 | 2023 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $20.93 | 2023 | Qelbree |
| Sanofi Pasteur INC. | $20.35 | 2025 | |
| Sumitomo Pharma America, INC. | $20.07 | 2024 | Gemtesa |
| Lundbeck LLC | $19.96 | 2025 | Rexulti |
| Biogen, INC. | $19.77 | 2024 | |
| Xeris Pharmaceuticals, INC. | $18.92 | 2025 | Gvoke Hypopen |
| Amarin Pharma, INC. | $16.89 | 2023 | |
| Vivus LLC | $16.84 | 2025 | Pancreaze |
| Amneal Pharmaceuticals LLC | $15.93 | 2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $15.75 | 2024 | Strensiq |
| Neos Therapeutics, LP | $14.84 | 2024 | Adzenys Xr-Odt |
| Abbott Laboratories | $14.17 | 2023 | Infinity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.67 | 2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $12.89 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Lahoti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.